ASC41

ASC41 is an experimental thyromimetic prodrug metabolized in the liver by CYP3A4 to an active form, ASC41-A, that is selective for thyroid hormone receptor beta

ASC41 is an experimental thyromimetic prodrug metabolized in the liver by CYP3A4 to an active form, ASC41-A, that is selective for thyroid hormone receptor beta.[1] It has been studied for the treatment of non-alcoholic fatty liver disease.[2]

In 2023, Viking Therapeutics filed a lawsuit against ASC41's developer, Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to, or identical to, VK2809.[3][4]

In 2024, Ascletis discontinued clinical development of ASC41 following unfavorable Phase II clinical trial results.[5][6]

References

  1. ^ Xie, Zhifu; Li, Yufeng; Cheng, Long; Huang, Yidan; Rao, Wanglin; Shi, Honglu; Li, Jingya (October 2, 2024). "Potential therapeutic strategies for MASH: from preclinical to clinical development". Life Metabolism. 3 (5) loae029. doi:10.1093/lifemeta/loae029. ISSN 2755-0230. PMC 11749562. PMID 39872142.
  2. ^ Fröhlich, Eleonore; Wahl, Richard (4 August 2022). "Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease". Metabolites. 12 (8): 718. doi:10.3390/metabo12080718. ISSN 2218-1989. PMC 9414490. PMID 36005590.
  3. ^ "Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache". Fierce Biotech. 3 January 2023. Retrieved 2 December 2023.
  4. ^ "Viking Therapeutics accuses competitor of pilfering proprietary information". Chemical & Engineering News. January 9, 2023. Viking infers that ASC41 is Ascletis's version of—if not the same compound as—VK2809
  5. ^ "Ascletis pulls FXR agonist from pipeline over phase 2 primary biliary cholangitis data". April 3, 2024.
  6. ^ "Ascletis Announces Strategic Decisions on FXR agonist ASC42" (Press release). April 3, 2024.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.